

Helen E Heslop

List of Publications by Citations

Source: <https://exaly.com/author-pdf/980912/helen-e-heslop-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356
papers

23,867
citations

77
h-index

150
g-index

400
ext. papers

27,159
ext. citations

5.6
avg, IF

6.53
L-index

#	Paper	IF	Citations
356	Inducible apoptosis as a safety switch for adoptive cell therapy. <i>New England Journal of Medicine</i> , 2011 , 365, 1673-83	59.2	1031
355	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , 2008 , 14, 1264-70	50.5	919
354	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. <i>Blood</i> , 2011 , 118, 6050-6	2.2	813
353	Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. <i>Nature Medicine</i> , 1996 , 2, 551-5	50.5	744
352	CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1822-6	15.9	709
351	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. <i>Blood</i> , 2010 , 115, 925-35	2.2	610
350	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1688-96	2.2	607
349	An inducible caspase 9 safety switch for T-cell therapy. <i>Blood</i> , 2005 , 105, 4247-54	2.2	477
348	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. <i>Nature Medicine</i> , 2006 , 12, 1160-6	50.5	460
347	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. <i>Blood</i> , 2013 , 121, 5113-23	2.2	399
346	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. <i>Blood</i> , 2013 , 122, 2965-73	2.2	390
345	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. <i>Blood</i> , 2014 , 123, 3750-9	2.2	381
344	HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. <i>JAMA Oncology</i> , 2017 , 3, 1094-1101	13.4	378
343	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. <i>Blood</i> , 2009 , 113, 6392-402	2.2	376
342	A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. <i>Molecular Therapy</i> , 2005 , 12, 933-41	11.7	365
341	Post-transplant lymphoproliferative disorders. <i>Annual Review of Medicine</i> , 2005 , 56, 29-44	17.4	345
340	Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. <i>Journal of Clinical Oncology</i> , 2014 , 32, 798-808	2.2	341

339	Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. <i>Journal of Experimental Medicine</i> , 2004 , 200, 1623-33	16.6	326
338	Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. <i>Blood</i> , 2005 , 105, 1898-904	2.2	300
337	Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. <i>Science Translational Medicine</i> , 2014 , 6, 242ra83	17.5	278
336	Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. <i>Blood</i> , 2009 , 114, 4283-92	2.2	272
335	HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 474-85	12.9	267
334	Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. <i>Blood</i> , 2002 , 99, 3179-87	2.2	267
333	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. <i>Molecular Therapy</i> , 2017 , 25, 2214-2224	11.7	249
332	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3547-3557	2.2	241
331	Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. <i>Molecular Therapy</i> , 2013 , 21, 2087-101	11.7	240
330	How I treat EBV lymphoproliferation. <i>Blood</i> , 2009 , 114, 4002-8	2.2	235
329	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. <i>Blood</i> , 2007 , 110, 2838-45	2.2	235
328	T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. <i>Blood</i> , 2006 , 108, 3890-7	2.2	231
327	An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. <i>Blood</i> , 2001 , 97, 835-43	2.2	225
326	Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients. <i>Blood</i> , 1998 , 92, 1549-1555	2.2	216
325	Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirectioned lymphocytes. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3462-3471	15.9	215
324	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. <i>Blood</i> , 2015 , 125, 3905-16	2.2	211
323	Clinical responses with T lymphocytes targeting malignancy-associated light chains. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2588-96	15.9	207
322	Prompt versus preemptive intervention for EBV lymphoproliferative disease. <i>Blood</i> , 2004 , 103, 3979-81	2.2	202

321	Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. <i>American Journal of Transplantation</i> , 2005 , 5, 2222-8	8.7	199
320	Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). <i>Blood</i> , 2006 , 108, 2942-9	2.2	197
319	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. <i>Blood</i> , 2011 , 117, 5835-49	2.2	193
318	Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. <i>Molecular Therapy</i> , 2012 , 20, 1622-32	11.7	193
317	T-cell therapy in the treatment of post-transplant lymphoproliferative disease. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 510-9	19.4	183
316	Adoptive cellular immunotherapy for EBV lymphoproliferative disease. <i>Immunological Reviews</i> , 1997 , 157, 217-22	11.3	183
315	Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. <i>Molecular Therapy</i> , 2013 , 21, 2113-21	11.7	170
314	Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. <i>Blood</i> , 2003 , 101, 1905-12	2.2	159
313	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. <i>Molecular Therapy</i> , 2017 , 25, 249-258	11.7	155
312	Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 913-24	4.7	154
311	Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. <i>Lancet, The</i> , 1997 , 350, 767-71	4.0	153
310	Inducible caspase-9 suicide gene controls adverse effects from alloplete T cells after haploidentical stem cell transplantation. <i>Blood</i> , 2015 , 125, 4103-13	2.2	149
309	Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. <i>Molecular Therapy</i> , 2009 , 17, 1779-87	11.7	144
308	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. <i>Clinical Cancer Research</i> , 2014 , 20, 2215-25	12.9	142
307	Regression of experimental medulloblastoma following transfer of HER2-specific T cells. <i>Cancer Research</i> , 2007 , 67, 5957-64	10.1	136
306	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016 , 6, 787-797	8	136
305	T cells for viral infections after allogeneic hematopoietic stem cell transplant. <i>Blood</i> , 2016 , 127, 3331-40	2.2	132
304	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. <i>Blood</i> , 2014 , 123, 3895-905	2.2	131

303	Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. <i>Blood</i> , 2003 , 102, 2292-9	2.2	129
302	Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). <i>Journal of Immunotherapy</i> , 2010 , 33, 305-15	5	128
301	Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. <i>Journal of Experimental Medicine</i> , 2004 , 199, 459-70	16.6	124
300	Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. <i>Blood</i> , 2002 , 100, 4059-66	2.2	124
299	Reversal of tumor immune inhibition using a chimeric cytokine receptor. <i>Molecular Therapy</i> , 2014 , 22, 1211-1220	11.7	121
298	Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. <i>Journal of Virology</i> , 2008 , 82, 546-54	6.6	112
297	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. <i>Molecular Therapy</i> , 2018 , 26, 2727-2737	11.7	107
296	Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. <i>Stem Cells and Development</i> , 1995 , 4, 73-9		106
295	Adoptive T cell therapy of cancer. <i>Current Opinion in Immunology</i> , 2010 , 22, 251-7	7.8	100
294	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1128-1139	2.2	98
293	Fine-tuning the CAR spacer improves T-cell potency. <i>Oncotmmunology</i> , 2016 , 5, e1253656	7.2	95
292	Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. <i>Blood</i> , 2010 , 115, 2695-703	2.2	95
291	Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. <i>Journal of Immunology</i> , 2002 , 168, 909-18	5.3	94
290	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3794-3804	2.2	90
289	CAR-T Cell Therapy for Lymphoma. <i>Annual Review of Medicine</i> , 2016 , 67, 165-83	17.4	89
288	Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2018 , 132, 89-100	2.2	88
287	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 1498-1505.e1	11.5	88
286	Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. <i>Blood</i> , 2009 , 113, 2442-50	2.2	88

285	Adoptive immunotherapy for EBV-associated malignancies. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1-10	1.9	88
284	Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1277-84	4.7	88
283	Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. <i>Molecular Therapy</i> , 2014 , 22, 623-633	11.7	83
282	Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 260-6	3.1	83
281	CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. <i>Science Translational Medicine</i> , 2015 , 7, 285ra63	17.5	78
280	Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. <i>Molecular Therapy</i> , 2009 , 17, 880-8	11.7	77
279	Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. <i>Human Gene Therapy</i> , 1994 , 5, 381-97	4.8	77
278	High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. <i>Blood</i> , 2011 , 117, 3353-62	2.2	75
277	Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. <i>Brain</i> , 2004 , 127, 996-1008	11.2	75
276	A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2007 , 109, 2657-62	2.2	74
275	Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001 , 93, 706-13	7.5	74
274	Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. <i>Transplantation</i> , 2001 , 72, 1078-86	1.8	72
273	Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). <i>Blood</i> , 2009 , 114, 4784-91	2.2	71
272	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2305-2321	4.7	68
271	An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. <i>Stem Cells</i> , 2010 , 28, 1107-15	5.8	68
270	Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. <i>American Journal of Transplantation</i> , 2005 , 5, 566-72	8.7	68
269	Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. <i>Journal of Immunology</i> , 2005 , 175, 4137-47	5.3	68
268	Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. <i>Blood</i> , 2013 , 121, 207-18	2.2	67

267	A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. <i>Cancer Gene Therapy</i> , 2004 , 11, 81-91	5.4	67
266	Definitions of histocompatibility typing terms. <i>Blood</i> , 2011 , 118, e180-3	2.2	64
265	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. <i>Cytotherapy</i> , 2010 , 12, 743-9	4.8	64
264	Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. <i>Molecular Therapy</i> , 2009 , 17, 1616-25	11.7	64
263	Posttransplant lymphoproliferative disease following liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2011 , 16, 274-80	2.5	63
262	Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. <i>Clinical Cancer Research</i> , 2011 , 17, 7058-66	12.9	61
261	Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. <i>Molecular Therapy</i> , 2011 , 19, 2258-68	11.7	61
260	Immunotherapy of hematologic malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2003 , 2003, 331-49	3.1	61
259	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. <i>Blood</i> , 2006 , 107, 1332-41	2.2	59
258	Adoptive immunotherapy for posttransplantation viral infections. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 143-55	4.7	59
257	Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. <i>Clinical Cancer Research</i> , 2013 , 19, 106-17	12.9	58
256	Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. <i>Transplantation</i> , 2002 , 74, 1050-2	1.8	58
255	Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 129, 176-83	11.5	56
254	Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. <i>Journal of Immunotherapy</i> , 2003 , 26, 241-56	5	56
253	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019 , 54, 1868-1880	4.4	55
252	Optimizing the production of suspension cells using the G-Rex "M" series. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014 , 1, 14015	6.4	55
251	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e76-e85	4.7	53
250	Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. <i>Clinical Transplantation</i> , 2006 , 20, 389-93	3.8	52

249	Immunotherapy for Epstein-Barr virus-associated cancers in children. <i>Oncologist</i> , 2003 , 8, 83-98	5.7	51
248	Antiviral T-cell therapy. <i>Immunological Reviews</i> , 2014 , 258, 12-29	11.3	49
247	Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. <i>Clinical Transplantation</i> , 2006 , 20, 689-94	3.8	48
246	Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 912-20	4.7	46
245	Immunotherapy for post-transplant lymphoproliferative disease. <i>British Journal of Haematology</i> , 2002 , 118, 728-40	4.5	45
244	Survivin-specific T cell receptor targets tumor but not T cells. <i>Journal of Clinical Investigation</i> , 2015 , 125, 157-68	15.9	45
243	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. <i>Nature Communications</i> , 2020 , 11, 3549	17.4	45
242	Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. <i>Cytotherapy</i> , 2011 , 13, 976-86	4.8	43
241	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. <i>British Journal of Haematology</i> , 2011 , 153, 76-82	4.5	43
240	Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. <i>Molecular Therapy</i> , 2012 , 20, 246-9	11.7	43
239	Impending challenges in the hematopoietic stem cell transplantation physician workforce. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1493-501	4.7	42
238	Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1345-50	4.7	42
237	Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. <i>Cancer Research</i> , 2002 , 62, 7195-9	10.1	42
236	Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 870-80	1.9	39
235	Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 1-8	4.7	39
234	Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. <i>Current Opinion in Hematology</i> , 2014 , 21, 476-81	3.3	38
233	Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. <i>Acta Haematologica</i> , 2003 , 110, 139-48	2.7	37
232	Adoptive T-cell transfer in cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2006 , 84, 281-9	5	36

231	Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. <i>Transplantation</i> , 2004 , 78, 755-7	1.8	36
230	Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. <i>Cytotherapy</i> , 2012 , 14, 7-11	4.8	35
229	The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1272-81	4.7	35
228	Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. <i>British Journal of Haematology</i> , 1991 , 77, 237-44	4.5	34
227	Cytotoxic T lymphocytes as immune-therapy in haematological practice. <i>British Journal of Haematology</i> , 2008 , 143, 169-79	4.5	33
226	Policy: Global standards for stem-cell research. <i>Nature</i> , 2016 , 533, 311-3	50.4	33
225	New ISSCR guidelines: clinical translation of stem cell research. <i>Lancet, The</i> , 2016 , 387, 1979-81	40	33
224	Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. <i>Current Opinion in Oncology</i> , 1999 , 11, 96-101	4.2	32
223	Engineered off-the-shelf therapeutic T cells resist host immune rejection. <i>Nature Biotechnology</i> , 2021 , 39, 56-63	44.5	32
222	Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 1990 , 75, 499-505	4.5	30
221	T lymphocytes targeting native receptors. <i>Immunological Reviews</i> , 2014 , 257, 39-55	11.3	29
220	Genetic modification of T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, S15-20	4.7	29
219	Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. <i>Human Gene Therapy</i> , 1994 , 5, 481-99	4.8	29
218	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. <i>Blood</i> , 2018 , 132, 2351-2361	2.2	29
217	Ex vivo gene transfer for improved adoptive immunotherapy of cancer. <i>Human Molecular Genetics</i> , 2011 , 20, R93-9	5.6	28
216	Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2004 , 75, 48-51	7.1	27
215	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies. <i>Blood</i> , 2019 , 134, 199-199	2.2	26
214	Antigen-specific T cell therapies for cancer. <i>Human Molecular Genetics</i> , 2015 , 24, R67-73	5.6	25

213	Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. <i>Molecular Therapy</i> , 2014 , 22, 1134-1138	11.7	25
212	T-cell therapy for viral infections. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 342-7	3.1	25
211	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. <i>Haematologica</i> , 2013 , 98, 533-7	6.6	25
210	Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. <i>Journal of Clinical Apheresis</i> , 1999 , 14, 154-6	3.2	25
209	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10508-10508	2.2	25
208	Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. <i>Human Immunology</i> , 2011 , 72, 1214-6	2.3	24
207	Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. <i>Trends in Molecular Medicine</i> , 1997 , 3, 24-30		24
206	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 837-42 ^{1.9}	1.9	24
205	Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. <i>Human Gene Therapy</i> , 1998 , 9, 1237-50	4.8	24
204	Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. <i>PLoS ONE</i> , 2011 , 6, e20267	3.7	24
203	Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. <i>Molecular Therapy</i> , 2016 , 24, 823-31	11.7	23
202	Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. <i>Leukemia and Lymphoma</i> , 1996 , 23, 213-20	1.9	23
201	Immunotherapy targeting EBV-expressing lymphoproliferative diseases. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 405-20	4.2	23
200	Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. <i>Cancer Treatment Reviews</i> , 2003 , 29, 3-10	14.4	23
199	Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). <i>Journal of Clinical Immunology</i> , 2015 , 35, 445-8	5.7	22
198	Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. <i>Molecular Therapy</i> , 2015 , 23, 179-83	11.7	21
197	The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. <i>Leukemia and Lymphoma</i> , 2000 , 39, 455-64	1.9	21
196	Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 273-81	4.7	20

195	Graft-versus-host reactions and bone-marrow transplantation. <i>Current Opinion in Immunology</i> , 1991 , 3, 752-7	7.8	19
194	Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. <i>British Journal of Haematology</i> , 1989 , 72, 122-6	4.5	19
193	Recent advances in T-cell immunotherapy for haematological malignancies. <i>British Journal of Haematology</i> , 2017 , 176, 688-704	4.5	18
192	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. <i>Clinical Cancer Research</i> , 2019 , 25, 7340-7350	12.9	18
191	Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1298-304	4.7	18
190	High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1643-1650	4.7	17
189	Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1266-72	4.7	17
188	A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. <i>Genomics</i> , 1997 , 39, 55-65	4.3	17
187	Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 342-7		17
186	Immunotherapy to reconstitute immunity to DNA viruses. <i>Seminars in Hematology</i> , 2002 , 39, 41-7	4	17
185	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). <i>Blood</i> , 2018 , 132, 680-680	2.2	16
184	Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 537-541	4.7	16
183	Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 408-422	4.7	16
182	Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. <i>Transplantation</i> , 2013 , 95, 519-26	1.8	15
181	Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. <i>Best Practice and Research in Clinical Haematology</i> , 2004 , 17, 401-13	4.2	15
180	Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation. <i>Blood</i> , 2013 , 122, 140-140	2.2	15
179	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. <i>Blood</i> , 2016 , 128, 1851-1851	2.2	15
178	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019 , 21, e13145	2.7	14

177	Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 595-7	4.7	14
176	A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. <i>Journal of Pediatric Hematology/Oncology</i> , 2007 , 29, 500-5	1.2	14
175	Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. <i>Annals of the New York Academy of Sciences</i> , 2003 , 996, 80-8	6.5	14
174	"Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. <i>Blood Advances</i> , 2019 , 3, 2571-2580	7.8	14
173	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S63	4.7	13
172	Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. <i>Cytotherapy</i> , 2011 , 13, 1128-39	4.8	13
171	Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens. <i>Blood</i> , 2015 , 126, 186-186	2.2	13
170	T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. <i>British Journal of Haematology</i> , 2019 , 187, 206-218	4.5	12
169	Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. <i>Cancer Immunology Research</i> , 2019 , 7, 528-533	12.5	12
168	Measuring gene-transfer efficiency. <i>Nature Medicine</i> , 1996 , 2, 1280-1	50.5	12
167	Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas. <i>Blood</i> , 2015 , 126, 185-185	2.2	12
166	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 375-386	0.6	12
165	Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. <i>Academic Radiology</i> , 2010 , 17, 479-88	4.3	11
164	Use of marker genes to investigate the mechanism of relapse and the effect of bone marrow purging in autologous transplantation for stage D neuroblastoma. <i>Human Gene Therapy</i> , 1993 , 4, 809-20	4.8	11
163	Allogeneic red blood cells fail to induce haemagglutinating antibodies or cellular alloimmunity in rats and are immunosuppressive. <i>Transplantation</i> , 1979 , 28, 144-8	1.8	11
162	Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. <i>British Journal of Haematology</i> , 2020 , 188, e84-e87	4.5	11
161	The safety and clinical effects of administering a multi-antigen-targeted T cell therapy to patients with multiple myeloma. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	11
160	Viral lymphomagenesis. <i>Current Opinion in Hematology</i> , 2006 , 13, 254-9	3.3	10

159	Gene-marking studies of hematopoietic cells. <i>International Journal of Hematology</i> , 2001 , 73, 14-22	2.3	10
158	Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. <i>British Journal of Haematology</i> , 1989 , 73, 468-74	4.5	10
157	Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1424-1431	4.7	9
156	Forecasting Cytokine Storms with New Predictive Biomarkers. <i>Cancer Discovery</i> , 2016 , 6, 579-80	24.4	9
155	Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. <i>Update on Cancer Therapeutics</i> , 2008 , 3, 33-41		9
154	Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. <i>Journal of Clinical Immunology</i> , 2000 , 20, 1-9	5.7	9
153	HAEMOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS. <i>British Journal of Haematology</i> , 1999 , 105, 2-6	4.5	9
152	Modulating TNF activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia 2020 , 8,		9
151	Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 143-51	3	8
150	Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. <i>Acta Haematologica</i> , 2003 , 110, 149-53	2.7	8
149	Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. <i>Human Gene Therapy</i> , 1996 , 7, 655-67	4.8	8
148	Graft versus leukaemia effects after marrow transplantation in man. <i>Best Practice and Research: Clinical Haematology</i> , 1991 , 4, 727-49		8
147	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2010 , 116, 829-829	2.2	8
146	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. <i>Blood</i> , 2021 , 137, 2585-2597	2.2	8
145	Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. <i>Molecular Therapy</i> , 2016 , 24, 736-45	11.7	7
144	Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. <i>Stem Cells and Development</i> , 1998 , 7, 217-24		7
143	Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. <i>Blood Advances</i> , 2019 , 3, 2689-2695	7.8	7
142	Immunotherapy: opportunities, risks and future perspectives. <i>Cytotherapy</i> , 2014 , 16, S120-9	4.8	6

141	Equal-opportunity treatment of EBV-PTLD. <i>Blood</i> , 2012 , 119, 2436-8	2.2	6
140	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target B-Light Immunoglobulin Chain. <i>Blood</i> , 2013 , 122, 506-506	2.2	6
139	Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10027-10027	2.2	6
138	Checkpoint inhibition and cellular immunotherapy in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 390-396	3.1	6
137	Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S10-S11	4.7	5
136	CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, S237	4.7	5
135	Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. <i>Cytotherapy</i> , 2018 , 20, 1182-1190	4.8	5
134	Combining drugs and biologics to treat nasopharyngeal cancer. <i>Molecular Therapy</i> , 2014 , 22, 8-9	11.7	5
133	Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 758-61	3	5
132	Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor. <i>Leukemia and Lymphoma</i> , 1990 , 3, 37-43	1.9	5
131	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1415-1425	2.2	5
130	Fall of the mutants: T cells targeting BCR-ABL. <i>Blood</i> , 2017 , 129, 539-540	2.2	4
129	Virus-specific T cells for malignancies - then, now and where to?. <i>Current Stem Cell Reports</i> , 2020 , 6, 17-29.8		4
128	Genetic engineering of T-cell receptors: TCR takes to titin. <i>Blood</i> , 2013 , 122, 853-4	2.2	4
127	A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma. <i>Blood</i> , 2020 , 136, 16-16	2.2	4
126	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-β to Patients with EBV-Associated Lymphomas. <i>Blood</i> , 2010 , 116, 560-560	2.2	4
125	Safety of Multiple Doses of CAR T Cells. <i>Blood</i> , 2015 , 126, 4425-4425	2.2	4
124	Allogeneic Stem Cell Transplantation in a Pediatric Patient with Whim Syndrome. <i>Blood</i> , 2015 , 126, 5528-5528		4

123	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3008-3008	2.2	4
122	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102293	2.2	4
121	T cell receptor repertoire of CD4 + and CD8 + T cell subsets in the allogeneic bone marrow transplant recipient. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 104-110	7.4	4
120	Exhausting alloreactivity of donor-derived CAR T cells. <i>Nature Medicine</i> , 2017 , 23, 147-148	50.5	3
119	Intravesicular Cidofovir for BK Hemorrhagic Cystitis in Pediatric Patients after Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S163-S164	4.7	3
118	New approaches in alternative donor transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S91-6	4.7	3
117	Equal opportunity CAR T cells. <i>Blood</i> , 2017 , 129, 3275-3277	2.2	3
116	Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. <i>Pediatric Radiology</i> , 1998 , 28, 492-6	2.8	3
115	The clone ranger?. <i>Molecular Therapy</i> , 2008 , 16, 1520-1	11.7	3
114	Gene transfer for the therapy of hematologic malignancy. <i>Current Opinion in Hematology</i> , 1995 , 2, 417-223	3	3
113	A method for preparing leucocyte depleted erythrocytes from rat blood. <i>Journal of Immunological Methods</i> , 1978 , 22, 389-91	2.5	3
112	Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. <i>Blood</i> , 2011 , 118, 155-155	2.2	3
111	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4622-4622	2.2	3
110	Excellent Outcomes for Pediatric Non-Malignant Diseases Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy in the Absence of a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, S13	4.7	3
109	Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. <i>Journal of Clinical Oncology</i> , 2021 , 39, 514-524	2.2	3
108	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021 , 100, 2529-2539 ³	3	3
107	Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. <i>Molecular Therapy</i> , 2019 , 27, 900-901	11.7	2
106	CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e54	1.2	2

105	Adoptive T-Cell Therapy to Prevent and Treat Human Metapneumovirus (hMPV) Infections Post Hematopoietic Stem Cell Transplant (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S170-174	4.7	2
104	CRISPR-Edited Immune Effectors: The End of the Beginning. <i>Molecular Therapy</i> , 2020 , 28, 995-996	11.7	2
103	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S111	4.7	2
102	Pharmacotherapy versus T lymphocytes for CMV. <i>Blood</i> , 2013 , 121, 3544-5	2.2	2
101	A less sour sweet; blocking galectin. <i>Blood</i> , 2011 , 117, 4165-6	2.2	2
100	Getting personal with melanoma. <i>Clinical Cancer Research</i> , 2011 , 17, 4189-91	12.9	2
99	Immunotherapy for malignancies and viral infections. <i>Current Opinion in Organ Transplantation</i> , 2000 , 5, 197-202	2.5	2
98	Gene therapy for paediatric leukaemia. <i>Expert Opinion on Biological Therapy</i> , 2001 , 1, 663-74	5.4	2
97	Cytokine gene transfer in the therapy of malignancy. <i>Best Practice and Research: Clinical Haematology</i> , 1994 , 7, 135-51		2
96	Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.. <i>Blood</i> , 2022 ,	2.2	2
95	Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1014-1014	2.2	2
94	Three-Module Signaling Endo-Domain Artificial T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.. <i>Blood</i> , 2004 , 104, 1747-1747	2.2	2
93	Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 5041-5041	2.2	2
92	Gene Transfer of IL-7R alpha (IL-7R α) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine.. <i>Blood</i> , 2007 , 110, 2756-2756	2.2	2
91	Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, Adv, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 501-501	2.2	2
90	Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 654-654	2.2	2
89	Sensitizing Burkitt lymphoma to EBV-CTLs. <i>Blood</i> , 2020 , 135, 1822-1823	2.2	2
88	Taking T-Cell Oncotherapy Off-the-Shelf. <i>Trends in Immunology</i> , 2021 , 42, 261-272	14.4	2

87	Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor-Associated Antigens. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S44-S45	4.7	2
86	Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3256-3263	1.9	2
85	Genetically engineered T-cells for adoptive immunotherapy. <i>Current Opinion in Molecular Therapeutics</i> , 2002 , 4, 467-75		2
84	Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 192-64.7		1
83	Suicide is painless. <i>Blood</i> , 2006 , 107, 2211-2212	2.2	1
82	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. <i>Blood</i> , 2020 , 136, 5-5	2.2	1
81	Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopoietic Stem Cells or Umbilical Cord Blood Transplants. <i>Blood</i> , 2008 , 112, 3909-3909	2.2	1
80	Adoptive Immunotherapy with Memory T Cells.. <i>Blood</i> , 2008 , 112, sci-25-sci-25	2.2	1
79	IL15 Enhances Proliferation and Effector Function of Antigen-Specific Cytotoxic T Lymphocytes (CTLs) and Mitigates the Suppressive Action of Regulatory T Cells (Tregs).. <i>Blood</i> , 2009 , 114, 4088-4088	2.2	1
78	Allogeneic Virus-Specific T Cells with HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease In Human Subjects. <i>Blood</i> , 2010 , 116, 1252-1252	2.2	1
77	Infusion of CD19-Directed and Multivirus Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation for B Cell Malignancies,. <i>Blood</i> , 2011 , 118, 4083-4083	2.2	1
76	Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. <i>Blood</i> , 2012 , 120, 224-224	2.2	1
75	Optimizing the Manufacture of CAR-T Cells for Clinical Applications. <i>Blood</i> , 2012 , 120, 348-348	2.2	1
74	Multicenter Study of Off-the-Shelf Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2012 , 120, 457-457	2.2	1
73	Safety and Clinical Efficacy Of Rapidly-Generated Virus-Specific T Cells With Activity Against Adv, EBV, CMV, HHV6 and BK Virus Administered After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2013 , 122, 148-148	2.2	1
72	Beyond CD19 CAR-T cells in lymphoma. <i>Current Opinion in Immunology</i> , 2021 , 74, 46-52	7.8	1
71	High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia. <i>Blood Advances</i> , 2021 ,	7.8	1
70	Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.. <i>Blood</i> , 2004 , 104, 2102-2102	2.2	1

69	The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV).. <i>Blood</i> , 2005 , 106, 81-81	2.2	1
68	Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells. <i>Blood</i> , 2018 , 132, 1685-1685.2	2.2	1
67	Broad Spectrum Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Therapy of Hematological Malignancy.. <i>Blood</i> , 2009 , 114, 4083-4083	2.2	1
66	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. <i>Blood</i> , 2011 , 118, 956-956	2.2	1
65	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 223-223	2.2	1
64	Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9115-9115	2.2	1
63	Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. <i>Blood Advances</i> , 2021 , 5, 4630-4633	7.8	1
62	Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study. <i>Blood</i> , 2020 , 136, 2-3	2.2	0
61	Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older. <i>Blood</i> , 2008 , 112, 2798-2798	2.2	0
60	Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial). <i>Blood</i> , 2021 , 138, 3847-3847	2.2	0
59	Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma. <i>Blood</i> , 2021 , 138, 1763-1763	2.2	0
58	Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2797-2803	4.4	0
57	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 885-907		0
56	Reply to S. Yuan et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2820-1	2.2	
55	TCR expression; quantitative easing by CD3. <i>Blood</i> , 2011 , 118, 3452-3	2.2	
54	Adoptive Immunotherapy920-935		
53	Adoptive cellular immunotherapy648-660		
52	Graft-versus-yogurt. <i>Blood</i> , 2004 , 103, 4000-4001	2.2	

51	Dimerize and die. <i>Blood</i> , 2004 , 103, 1177-1178	2.2
50	To T-cell deplete or not. <i>Blood</i> , 2005 , 106, 2932-2932	2.2
49	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. <i>Blood</i> , 2021 , 138, 471-471	2.2
48	Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 158-158	2.2
47	LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.. <i>Blood</i> , 2004 , 104, 3276-3276	
46	Rasburicase Improves Renal Function and Uric Acid Nephropathy in Patients Developing Acute Renal Failure after Conditioning for Hematopoietic Stem Cell Transplant (HSCT).. <i>Blood</i> , 2004 , 104, 1142-1142	
45	Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.. <i>Blood</i> , 2004 , 104, 2112-2112	2.2
44	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. <i>Blood</i> , 2004 , 104, 3855-3855	2.2
43	High Incidence but Low Morbidity of Early Cytomegalovirus (CMV) Infections Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation with Alemtuzumab and Ganciclovir Prophylaxis.. <i>Blood</i> , 2004 , 104, 5098-5098	2.2
42	Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.. <i>Blood</i> , 2004 , 104, 1743-1743	
41	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. <i>Blood</i> , 2005 , 106, 2052-2052	2.2
40	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. <i>Blood</i> , 2005 , 106, 2746-2746	2.2
39	Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells.. <i>Blood</i> , 2005 , 106, 5540-5540	2.2
38	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005 , 106, 773-773	2.2
37	T Cell Immunotherapy for Adenoviral Infections of Stem Cell Transplant Recipients.. <i>Blood</i> , 2006 , 108, 591-591	2.2
36	Transgenic Expression of IL15 Selectively Expands Antigen Specific Cytotoxic T Cells (CTLs) Enhancing Their Anti-Tumor Effect In Vivo.. <i>Blood</i> , 2006 , 108, 1721-1721	2.2
35	Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML).. <i>Blood</i> , 2007 , 110, 2761-2761	2.2
34	Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens. <i>Blood</i> , 2018 , 132, 2693-2693	2.2

- 33 Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis. *Blood*, **2019**, 134, 3273-3273 2.2
- 32 Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center.. *Journal of Clinical Oncology*, **2020**, 38, e19525-e19525 2.2
- 31 Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells. *Blood*, **2014**, 124, 2439-2439 2.2
- 30 T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors. *Blood*, **2014**, 124, 2434-2434 2.2
- 29 Matched Unrelated Allogeneic Stem Cell Transplantation for Patients with Congenital Amegakaryocytic Thrombocytopenia: Texas Children's Hospital Experience. *Blood*, **2015**, 126, 5529-5529^{2.2}
- 28 Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant. *Blood*, **2015**, 126, 622-622^{2.2}
- 27 Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years. *Blood*, **2015**, 126, 1926-1926 2.2
- 26 Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma. *Blood*, **2016**, 128, 2990-2990 2.2
- 25 Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBVCTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506). *Blood*, **2008**, 112, 3536-3536 2.2
- 24 Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. *Blood*, **2008**, 112, 230-230 2.2
- 23 Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients.. *Blood*, **2008**, 112, 2207-2207 2.2
- 22 The Side-Population of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy. *Blood*, **2008**, 112, 2620-2620 2.2
- 21 Rapid Generation of Antigen-Specific T Cells for Pre-Clinical and Clinical Applications Using a Novel Mini Cell Bioreactor. *Blood*, **2008**, 112, 208-208 2.2
- 20 Vaccination Strategies for Patients with B-CLL.. *Blood*, **2008**, 112, 2106-2106 2.2
- 19 Exploiting Cytokine Secretion to Rapidly Produce Multivirus-Specific T Cells for Adoptive Immunotherapy. *Blood*, **2008**, 112, 4594-4594 2.2
- 18 Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. *Blood*, **2008**, 112, 3505-3505 2.2
- 17 Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9. *Blood*, **2008**, 112, 3534-3534 2.2
- 16 Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia. *Blood*, **2008**, 112, 3899-3899 2.2

- 15 Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy. *Blood*, **2008**, 112, 824-824 2.2
- 14 Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy.. *Blood*, **2009**, 114, 504-504 2.2
- 13 An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies.. *Blood*, **2009**, 114, 1444-1444 2.2
- 12 Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience.. *Blood*, **2009**, 114, 3212-3212 2.2
- 11 Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant.. *Blood*, **2009**, 114, 4089-4089 2.2
- 10 The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. *Blood*, **2010**, 116, 3949-3949 2.2
- 9 CASPALLO: Phase I Clinical Trial of Allogeneic T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation. *Blood*, **2010**, 116, 559-559 2.2
- 8 Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. *Blood*, **2011**, 118, 4043-4043 2.2
- 7 Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. *Blood*, **2011**, 118, 1913-1913 2.2
- 6 Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency. *Blood*, **2011**, 118, 644-644 2.2
- 5 Naive T Cell-Derived CTL Recognize Atypical Epitopes of CMVpp65 with Higher Avidity Than CMV-Seropositive Donor-Derived CTL as a Basis for Treatment of Post-Transplant Viral Infection by Adoptive Transfer of T Cells From Virus-naive Donors. *Blood*, **2011**, 118, 3002-3002 2.2
- 4 Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca).. *Journal of Clinical Oncology*, **2012**, 30, 2558-2558 2.2
- 3 Whole genome sequencing of sporadic Burkitt lymphoma in HIV-infected and uninfected patients.. *Journal of Clinical Oncology*, **2013**, 31, 8577-8577 2.2
- 2 A Non-fratricidal T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies. *Blood*, **2013**, 122, 141-141 2.2
- 1 Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. *Transplantation and Cellular Therapy*, **2021**, 27, 785.e1-785.e6 2.2